当前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 79750LILRB4 NFAT-Luciferase Reporter Jurkat Recombinant Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
Jurkat cells stably expressing human LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4, GenBank Accession #NM_001278426) and the firefly luciferase gene under the control of NFAT response elements. Activation of NFAT in these cells can be monitored by measuring luciferase activity.
The expression of human LILRB4 was confirmed by flow cytometry analysis. The functionality of the cell line was validated using an anti-CD3 agonist antibody. Treatment of LILRB4-expressing NFAT-Luciferase reporter Jurkat cells with the anti-CD3 agonist antibody induced luciferase activity at a reduced level compared to the same treatment in the NFAT-Luciferase Reporter Jurkat cells (parental cells), consistent with the inhibitory function of LILRB4.
Illustration of the LILRB4 NFAT luciferase reporter Jurkat cell line.
In response to TCR activation, LILRB4 is tyrosine phosphorylated by Src-family kinases such as Lck or Fyn, which triggers recruitment of SH2 domain-containing phosphatases, leading to attenuation of the T cell activation signals.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。